European Neuropsychopharmacology
Volume 21, Issue 5 , Pages 355-361 , May 2011

Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: Deregulation in schizophrenia

  • Efrat Dresner

      Affiliations

    • Adams Super Center for Brain Studies, and Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel
    • ,
  • Galila Agam

      Affiliations

    • Psychiatry Research Unit and Department of Clinical Biochemistry, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
    • Mental Health Center, Beer-Sheva, Israel
    • ,
  • Illana Gozes

      Affiliations

    • Adams Super Center for Brain Studies, and Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Israel
    • Corresponding Author InformationCorresponding author. The Lily and Avraham Gildor Chair for the Investigation of Growth Factors, Laboratory for Molecular Neuroendocrinology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel. Tel.: +972 3 640 7240; fax: +972 3 640 8541.

Received 2 March 2010 ,Revised 12 May 2010 ,Accepted 12 June 2010.

References 

  1. Akiyama H, Sugiyama A, Uzawa K, Fujisawa N, Tashiro Y, Tashiro F. Implication of Trip15/CSN2 in early stage of neuronal differentiation of P19 embryonal carcinoma cells. Dev. Brain Res. 2003;140:45–56
  2. Benitez-King G, Ramirez-Rodriguez G, Ortiz L, Meza I. The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 2004;3:515–533
  3. Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR, et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc. Natl. Acad. Sci. USA. 2005;102:8627–8632
  4. Cannon TD, Hennah W, van Erp TG, Thompson PM, Lonnqvist J, Huttunen M, et al. Association of DISC1/TRAX haplotypes with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch. Gen. Psychiatry. 2005;62:1205–1213
  5. Chubb JE, Bradshaw NJ, Soares DC, Porteous DJ, Millar JK. The DISC locus in psychiatric illness. Mol. Psychiatry. 2008;13:36–64
  6. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. J. Neurochem. 2006;98:973–984
  7. Enomoto A, Asai N, Namba T, Wang Y, Kato T, Tanaka M, et al. Roles of disrupted-in-schizophrenia 1-interacting protein girdin in postnatal development of the dentate gyrus. Neuron. 2009;63:774–787
  8. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 2009;35:528–548
  9. Fradley RL, O'Meara GF, Newman RJ, Andrieux A, Job D, Reynolds DS. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav. Brain Res. 2005;163:257–264
  10. Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I. Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol. 2004;1:193–199
  11. Furman S, Hill JM, Vulih I, Zaltzman R, Hauser JM, Brenneman DE, et al. Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci. Lett. 2005;373:73–78
  12. Gong CX, Shaikh S, Grundke-Iqbal I, Iqbal K. Inhibition of protein phosphatase-2B (calcineurin) activity towards Alzheimer abnormally phosphorylated tau by neuroleptics. Brain Res. 1996;741:95–102
  13. Gozes I, Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr. Alzheimer Res. 2007;4:507–509
  14. Gozes I, Spivak-Pohis I. Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate. Curr. Alzheimer Res. 2006;3:197–199
  15. Gozes I, Stewart A, Morimoto B, Fox A, Sutherland K, Schmeche D. Addressing Alzheimer's disease tangles: from NAP to AL-108. Curr. Alzheimer Res. 2009;6:455–460
  16. Hayashi MA, Portaro FC, Bastos MF, Guerreiro JR, Oliveira V, Gorrao SS, et al. Inhibition of NUDEL (nuclear distribution element-like)-oligopeptidase activity by disrupted-in-schizophrenia 1. Proc. Natl. Acad. Sci. USA. 2005;102:3828–3833
  17. Hunsberger J, Austin DR, Henter ID, Chen G. The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues Clin. Neurosci. 2009;11:333–348
  18. Javitt DC. Effects of intranasal AL-108 (davunetide) on neurocognition and functional outcome in schizopherenia. Schizophr. Res. 2010;117:118–119
  19. Koga M, Ishiguro H, Yazaki S, Horiuchi Y, Arai M, Niizato K, et al. Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia. Hum. Mol. Genet. 2009;18:2483–2494
  20. Kushnir M, Dresner E, Mandel S, Gozes I. Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. J. Neurochem. 2008;105:537–545
  21. Mandel S, Gozes I. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J. Biol. Chem. 2007;282:34,448–34,456
  22. Mandel S, Rechavi G, Gozes I. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev. Biol. 2007;303:814–824
  23. Mandel S, Spivak-Pohis I, Gozes I. ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J. Mol. Neurosci. 2008;35:127–141
  24. Nadri C, Dean B, Scarr E, Agam G. GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Schizophr. Res. 2004;71:377–382
  25. Ohnuma T, Kato H, Arai H, Faull RL, McKenna PJ, Emson PC. Gene expression of PSD95 in the prefrontal cortex and hippocampus in schizophrenia. NeuroReport. 2000;11:3133–3137
  26. Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, et al. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res. Dev. Brain Res. 2003;144:83–90
  27. Roberts SB, Hill CA, Dean B, Keks NA, Opeskin K, Copolov DL. Confirmation of the diagnosis of schizophrenia after death using DSM-IV: a Victorian experience. Aust. NZ J. Psychiatry. 1998;32:73–76
  28. Shimizu H, Iwayama Y, Yamada K, Toyota T, Minabe Y, Nakamura K, et al. Genetic and expression analyses of the STOP (MAP6) gene in schizophrenia. Schizophr. Res. 2006;84:244–252
  29. Steingart RA, Gozes I. Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Mol. Cell. Endocrinol. 2006;252:148–153
  30. Van Broeckhoven C, Verheyen G. Report of the chromosome 18 workshop. Am. J. Med. Genet. 1999;88:263–270
  31. Vulih-Shultzman I, Pinhasov A, Mandel S, Grigoriadis N, Touloumi O, Pittel Z, et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J. Pharmacol. Exp. Ther. 2007;323:438–449
  32. Zamostiano R, Pinhasov A, Gelber E, Steingart RA, Seroussi E, Giladi E, et al. Cloning and characterization of the human activity-dependent neuroprotective protein. J. Biol. Chem. 2001;276:708–714

PII: S0924-977X(10)00117-3

doi: 10.1016/j.euroneuro.2010.06.004

European Neuropsychopharmacology
Volume 21, Issue 5 , Pages 355-361 , May 2011

Article Tools

* Image Usage & Resolution